Ornida IV Infusion contains Ornidazole 500 mg, a nitroimidazole class antimicrobial agent effective against a broad spectrum of anaerobic bacteria and protozoa. It is indicated for the treatment of infections caused by susceptible anaerobic organisms, including bacterial vaginosis, trichomoniasis, amoebiasis, giardiasis, and anaerobic bacterial infections of the respiratory tract, skin, soft tissues, bones, joints, and intra-abdominal cavity. Ornidazole exerts its antimicrobial effect by disrupting the DNA synthesis of anaerobic pathogens, leading to cell death. The intravenous formulation ensures rapid and complete bioavailability, making it suitable for patients who require immediate therapeutic levels or are unable to tolerate oral administration. Dosage and duration of therapy should be individualized based on the severity and type of infection, patient response, and renal and hepatic function. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with known hypersensitivity to nitroimidazoles. Ornida IV Infusion should be administered under medical supervision, with monitoring for therapeutic efficacy and potential adverse effects. It is important to complete the full prescribed course to prevent resistance development and relapse.